Clinical Medicine College, Affiliated Hospital of Hebei University, Hebei University, Baoding, 071000, China.
Department of Neurosurgery, Affiliated Hospital of Hebei University, Hebei University, Baoding, 071000, China.
Med Oncol. 2023 May 18;40(6):181. doi: 10.1007/s12032-023-02047-0.
Brain metastasis (BM) is a critical cause of morbidity and mortality in patients with breast cancer (BC). Compared with other cancer cells, BC cells (BCs) exhibit special features in the metastatic process. However, the underlying mechanisms are still unclear, especially the crosstalk between tumour cells and the microenvironment. To date, novel therapies for BM, including targeted therapy and antibody‒drug conjugates, have been developed. Due to an improved understanding of the blood‒brain barrier (BBB) and blood-tumour barrier (BTB), the development and testing of therapeutic agents in clinical phases have substantially increased. However, these therapies face a major challenge due to the low penetration of the BBB or BTB. As a result, researchers have increasingly focused on finding ways to promote drug penetration through these barriers. This review provides an updated overview of breast cancer brain metastases (BCBM) and summarizes the newly developed therapies for BCBM, especially drugs targeting the BBB or BTB.
脑转移(BM)是乳腺癌(BC)患者发病率和死亡率的重要原因。与其他癌细胞相比,BC 细胞(BCs)在转移过程中表现出特殊的特征。然而,其潜在机制尚不清楚,特别是肿瘤细胞与微环境之间的串扰。迄今为止,针对 BM 的新型治疗方法,包括靶向治疗和抗体药物偶联物,已经得到了发展。由于对血脑屏障(BBB)和血肿瘤屏障(BTB)的理解有所提高,在临床阶段开发和测试治疗剂的数量大大增加。然而,由于 BBB 或 BTB 的通透性低,这些治疗方法面临着重大挑战。因此,研究人员越来越关注寻找促进药物穿透这些屏障的方法。本综述提供了对乳腺癌脑转移(BCBM)的最新概述,并总结了新开发的 BCBM 治疗方法,特别是针对 BBB 或 BTB 的药物。